Neonatal Medicine Expert Witness GA 532227

Expertise Description

I am an experienced neonatal medicine expert witness with more than a decade of experience working in the medical field. My expertise is in general pediatrics; the link between early life growth trajectories on future cardiovascular risk; the relationship between fetal growth restriction and visceral adiposity in later life; and premature cardiovascular health: including hypertension, arterial stenosis, aneurysm formation, and Moya Moya. I am offering my services as a neonatal medicine expert witness.

Neonatal and Perinatal Medicine Expert 506320 CA(N)

Expertise Description

I have more than 10 years of experience in Pediatric and Neonatal-Perinatal medicine and a recognized national expert at assessing standards of quality and safe care, and implementation of “best practice” in neonatal medicine. I am a Medical Director, Quality and Performance Improvement, Newborn and Infant Critical Care Unit at a children’s hospital. I am also Director of Quality Improvement and Safety for the Division of Neonatology at a school of medicine. This includes leading all Root Cause Analyses for all adverse outcomes, serious hospital acquired infections, and serious safety events as well as leading and implementing corrective action. As an Assistant Clinical Professor of Pediatrics at this school of medicine, I am an expert at assessing, implementing and teaching evidence-based medicine.

Pharmaceutical Economics Expert 324124 CA(S)

Expertise Description

I have more than 30 years experience in Pharmaceutical Economics. My areas of expertise include health economics, pharmaceutical economics, government health care programs (e.g., Medicare, Medicaid, Affordable Care Act), health care market organization, drug legalization policy, cost effectiveness & cost/benefit analysis, comparative effectiveness and outcomes research, hospital costs, treatment selection bias, microeconometrics, health care demand estimation, vaccine policy, HIV/AIDS medical costs and epidemiology, health insurance reform and consulting, evidence-based disease management, and economic assessment of medical technology.